ANDA 209695, held by Adaptis. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 209695 (Fluoxetine Hydrochloride), held by Adaptis, was first approved by FDA on Nov 20, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 20, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluoxetine HydrochlorideEQ 60MG BASE · tablet;oral | Fluoxetine Hydrochloride | Rx |
| Sep 26, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 26, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 20, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters